S. 1954 · 119th Congress · Health
Biosimilar Red Tape Elimination Act
A bill that started in the Senate. To become law it must pass the Senate and the House in identical form and be signed by the President.
Where it stands
Cleared committee — waiting for a Senate vote
- Introduced — doneJun 4, 2025
- Cleared committee — doneJul 27, 2026
- Passed the Senate — not yet
- Passed the House — not yet
- Sent to the President — not yet
- Became law — not yet
Latest action · Jul 27, 2026
Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
What this bill means
In plain English
This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products.
From the official summary by the Congressional Research Service (introduced in senate version). The full summary is below.
If it passes
It becomes federal law, and what it describes takes effect on the dates written into the bill.
What still has to happen
- 1Senate leaders must schedule it for a vote, and the Senate must pass it.
- 2Then the House must pass it in the same form.
- 3Then it goes to the President to sign or veto.
If it doesn't pass
- Nothing changes. The law stays exactly as it is today — a bill has no effect unless it is enacted.
- This bill expires when the 119th Congress ends on Jan 3, 2027. To try again, a member would have to introduce it as a new bill in the next Congress and start over.
Read the full official summaryCongressional Research Service · Introduced in Senate · Jun 4, 2025
This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products.
A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law. Further, the first biosimilar deemed interchangeable with a given reference product is awarded a period of marketing exclusivity.
The bill eliminates additional requirements for demonstrating interchangeability so that all licensed biosimilars are deemed interchangeable with their reference products. (Draft guidance released by the FDA in 2024 proposed to make some of these interchangeability requirements optional, including studies related to the safety of switching between use of the biosimilar and reference product. It has not been finalized.)
This change takes effect 60 days after the bill is enacted, and previously licensed biosimilars must be deemed interchangeable with their reference products on that date. However, the bill preserves the exclusivity period for first interchangeable biosimilars licensed before the bill’s enactment. For example, if a new biosimilar licensed after the bill takes effect relies on the same reference product as an existing biosimilar that is subject to an unexpired exclusivity period, the new biosimilar is not deemed interchangeable with the reference product until the exclusivity period has ended.
Who started it
Sponsor — the member who introduced it

Introduced in the Senate on Jun 4, 2025.
See Mike Lee's votes and donorsCosponsors — members who signed on in support
5cosponsors
3 Democrats · 2 Republicans
Members of both parties have signed on.
- Ben Ray LujánD-NM
- Rand PaulR-KY
- Margaret Wood HassanD-NH
- Eric SchmittR-MO
- Jon OssoffD-GA
Committees handling it
A bill is sent to the committee that covers its subject. The committee decides whether it ever reaches a vote of the full chamber.
Health, Education, Labor, and Pensions Committee
Senate
- Reported By · Jul 27, 2026
- Markup By · Jun 17, 2026
- Referred To · Jun 4, 2025
- Referred To · Jun 4, 2025
Full timeline
Every recorded action on S. 1954, from the day it was introduced to the most recent, exactly as the House, the Senate, and the Library of Congress logged it.
- IntroducedSenate
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Cleared committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Senate
Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
Have a view on S. 1954? Your leaders vote on it.
Tell your senators and your representative where you stand. We fill in who represents you and reference this bill in the letter.
Write your leaders about thisSource: Congress.gov record for S. 1954(opens in new tab)